Drug
Relugolix
Relugolix: highest development phase Phase 3, developed by Sumitomo Pharma, United Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sumitomo Pharma, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Relugolix NCT05605964 | Phase 3 | Prostate Cancer |
| Relugolix NCT05765500 | Phase 2 | Prostate Cancer |
Latest
Follow Relugolix on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.